Citigroup
TTPH

Citigroup’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Citigroup’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-297
Closed -$2K – 7892
2019
Q3 		$2K Sell
297
-102
-26% -$680 ﹤0.01% 7582
2019
Q2 		$4K Sell
399
-262
-40% -$4.82K ﹤0.01% 7552
2019
Q1 		$18K Sell
661
-263
-28% -$6.69K ﹤0.01% 7023
2018
Q4 		$21K Buy
924
+269
+41% +$10.5K ﹤0.01% 6866
2018
Q3 		$36K Buy
655
+124
+23% +$7.92K ﹤0.01% 6787
2018
Q2 		$38K Sell
531
-18
-3% -$1.27K ﹤0.01% 6500
2018
Q1 		$33K Buy
549
+525
+2,188% +$46.1K ﹤0.01% 6454
2017
Q4 		$3K Buy
24
+13
+118% +$1.67K ﹤0.01% 7356
2017
Q3 		$1K Sell
11
-5
-31% -$669 ﹤0.01% 7198
2017
Q2 		$2K Sell
16
-92
-85% -$14.2K ﹤0.01% 7068
2017
Q1 		$20K Sell
108
-1,791
-94% -$201K ﹤0.01% 6264
2016
Q4 		$152K Buy
1,899
+1,389
+272% +$110K ﹤0.01% 5509
2016
Q3 		$39K Buy
510
+19
+4% +$1.52K ﹤0.01% 5837
2016
Q2 		$42K Sell
491
-1,237
-72% -$113K ﹤0.01% 5678
2016
Q1 		$160K Buy
1,728
+1,018
+143% +$102K ﹤0.01% 5300
2015
Q4 		$142K Buy
710
+624
+726% +$125K ﹤0.01% 5057
2015
Q3 		$13K Sell
86
-117
-58% -$85.9K ﹤0.01% 6311
2015
Q2 		$193K Sell
203
-172
-46% -$141K ﹤0.01% 4462
2015
Q1 		$275K Sell
375
-170
-31% -$128K ﹤0.01% 4242
2014
Q4 		$432K Buy
545
+444
+440% +$239K ﹤0.01% 4016
2014
Q3 		$40K Sell
101
-63
-38% -$16.9K ﹤0.01% 5463
2014
Q2 		$44K Buy
164
+56
+52% +$12K ﹤0.01% 5253
2014
Q1 		$24K Sell
108
-132
-55% -$36.8K ﹤0.01% 5935
2013
Q4 		$65K Buy
240
+239
+23,900% +$57K ﹤0.01% 5570
2013
Q3 		$0 Sell
1
-99
-99% -$17.3K ﹤0.01% 7076
2013
Q2 		$14K Buy
+100
New +$15.8K ﹤0.01% 5973

Other funds holding TTPH

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citigroup's TTPH Position: Q4 2019 in Review

Citigroup sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q4 2019, closing a stake of 297 shares — an estimated $2K sold.

Citigroup first reported a position in TTPH in Q2 2013 and held it in 26 quarters. The position peaked at $432K in Q4 2014. 23 funds tracked by Wall St. Rank hold TTPH as of Q4 2019.

  • Citigroup reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Citigroup sold 297 Tetraphase Pharmaceuticals, Inc. shares in Q4 2019, an estimated $2K.
  • Citigroup first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2013 and held it in 26 quarters.
  • Citigroup's Tetraphase Pharmaceuticals, Inc. position peaked at $432K in Q4 2014.
  • 23 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q4 2019.

Based on Citigroup's 13F filing for Q4 2019, filed 12 Feb 2020.